At a Glance
- Company: Thalia Therapeutics plc (formerly N4 Pharma PLC)
- Location: UK (AIM-listed)
- Deal value: Name change (no monetary transaction)
- Focus area: RNA therapeutics, Nuvec® delivery for oncology/cardiology
- Next steps: Advance pipeline; website update at thaliatx.com
What happened?
N4 Pharma PLC’s shareholders approved the name change to Thalia Therapeutics plc at a general meeting on 17 March 2026, effective immediately upon Companies House registration and on the London Stock Exchange from 18 March 2026. The ticker shifts from N4P to THAT, with no impact on shareholder holdings or existing share certificates.
Why does it matter?
The rebrand signals a strategic evolution from platform development to a therapeutics-focused biotech, emphasising RNA-based treatments for high-unmet-need areas like cancer and cardiovascular disease. It positions Thalia to capitalise on RNA’s rapid growth while leveraging Nuvec®—a proprietary, non-viral gene delivery system—for differentiated delivery efficiency and safety.
Who’s behind it?
Thalia Therapeutics, formerly N4 Pharma, is a pre-clinical UK biotech now led by CEO Dr David Solomon (appointed February 2026). The firm recently initiated a dual-acting siRNA programme targeting PCSK9 and Lp(a) for cardiovascular risk reduction, alongside oncology assets using Nuvec®.
How was it achieved?
The transition followed a board strategic review, shareholder approval via special resolution and Companies House filing. Nuvec® remains central, enabling RNA therapeutics without viral vectors; the rebrand clarifies focus amid expanding pipeline, including patent filings for novel siRNAs.
What’s next?
Thalia will prioritise Nuvec®-enabled RNA programmes in cardiovascular and oncology indications, with potential asset acquisitions to accelerate commercial timelines. Updated investor resources available at thaliatx.com from 18 March 2026.
What are people saying?
CEO Dr David Solomon: “Reflects our strategic evolution… well positioned to advance innovative treatments.”